List of Excipients in Branded Drug ELAVIL 25 MG

Generic Drugs Containing ELAVIL 25 MG

Company	Ingredient	NDC	Excipient
Thompson Medical Solutions Llc	amitriptyline hydrochloride	69874-422	CELLULOSE, MICROCRYSTALLINE
Thompson Medical Solutions Llc	amitriptyline hydrochloride	69874-422	D&C YELLOW NO. 10
Thompson Medical Solutions Llc	amitriptyline hydrochloride	69874-422	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in ELAVIL 25 MG?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 2

Elavil 25 mg Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Elavil 25 mg is the historical branded tablet formulation of amitriptyline hydrochloride, a tricyclic antidepressant. Its active pharmaceutical ingredient is generic, inexpensive, and no longer protected by meaningful composition-of-matter exclusivity. Commercial value therefore depends on formulation differentiation, tolerability, dosing convenience, supply reliability, and regulatory positioning rather than on the Elavil brand itself.

The strongest opportunities are a palatable liquid, orally disintegrating tablet, low-dose titration product, abuse-resistant unit-dose packaging, and formulations that address lactose intolerance, sugar restrictions, or swallowing difficulty. A conventional immediate-release tablet remains the lowest-cost pathway but has limited defensibility.

What is Elavil 25 mg and how is it regulated?

Elavil 25 mg contains amitriptyline hydrochloride equivalent to 25 mg of amitriptyline. The product was marketed as an immediate-release oral tablet for depressive illness. Amitriptyline is also widely used off-label for neuropathic pain, migraine prevention, sleep disorders, and functional gastrointestinal disorders.

Historical Elavil labeling identifies conventional tablet excipients such as lactose, dibasic calcium phosphate, corn starch, magnesium stearate, and talc, with colorants varying by tablet strength. Current generic amitriptyline tablets use manufacturer-specific excipient systems and may include microcrystalline cellulose, pregelatinized starch, colloidal silicon dioxide, crospovidone, povidone, sodium starch glycolate, and film-coating materials.[1]

Attribute	Elavil 25 mg
Active ingredient	Amitriptyline hydrochloride
Strength	25 mg
Dosage form	Immediate-release tablet
Pharmacologic class	Tricyclic antidepressant
US regulatory pathway	Historical NDA product; generic products generally approved under ANDA
Current branded status	Elavil is no longer the principal US commercial source
Generic status	Multiple amitriptyline hydrochloride products
Orange Book patent relevance	No meaningful active ingredient patent barrier
Primary formulation issue	Taste, swallowability, dose flexibility, and excipient tolerability

The FDA Orange Book remains the relevant source for listed patents, exclusivity, therapeutic-equivalence codes, and reference-listed-drug information.[2]

What excipients were used in the historical Elavil 25 mg tablet?

The historical tablet used a conventional compressed-tablet platform. The core formulation relied on fillers, binders, disintegrants, lubricants, and glidants rather than on a modified-release delivery system.

Historical excipient functions

Excipient class	Likely role in the historical tablet	Commercial relevance
Lactose or another diluent	Provides tablet bulk and improves compression	Can create a lactose-intolerance or labeling objection
Dibasic calcium phosphate	Filler and compression aid	Improves hardness but may increase density
Corn starch	Binder and disintegrant	Low-cost, familiar, but moisture-sensitive
Magnesium stearate	Lubricant	Excess levels can slow dissolution
Talc	Glidant or antiadherent	Supports processing but requires controlled quality
Colorants	Strength identification	Creates regulatory and consumer-preference issues
Coating materials, where used	Appearance, handling, taste masking	Can improve differentiation

The exact excipient list must be tied to the specific historical label, manufacturer, and market. Generic products are not required to duplicate every inactive ingredient in the branded product. They must meet applicable quality, bioequivalence, labeling, and inactive-ingredient requirements.[1,3]

How should a modern excipient strategy for amitriptyline 25 mg be designed?

A modern formulation should begin with the product objective. A standard generic tablet, a patient-friendly dosage form, and a lifecycle-management product require different excipient choices.

1. Standard immediate-release tablet

The lowest-cost formulation would use lactose or microcrystalline cellulose as the primary diluent, a starch-based or superdisintegrant system, magnesium stearate as lubricant, and colloidal silicon dioxide as glidant.

A practical high-volume platform could include:

• Microcrystalline cellulose for compactibility
• Mannitol or lactose for bulk and mouthfeel
• Crospovidone or croscarmellose sodium for rapid disintegration
• Low-level colloidal silicon dioxide for flow
• Magnesium stearate at a controlled concentration
• A simple film coat for identification and handling

This formulation is suitable for ANDA development if it delivers comparable dissolution and bioavailability. It has limited patent value because each excipient is widely used and the formulation can often be designed around ordinary pharmaceutical practice.

2. Lactose-free tablet

A lactose-free tablet has a clear commercial rationale. It can use microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a combination of these materials.

Mannitol is attractive when mouthfeel, low hygroscopicity, and rapid disintegration are priorities. Microcrystalline cellulose supports compression but can create a chalky mouthfeel in chewable or orally disintegrating products. Dibasic calcium phosphate gives hardness and low cost but may make a tablet dense and less suitable for rapid oral dispersion.

The formulation should avoid unnecessary excipient complexity. Each additional excipient increases supplier qualification, analytical testing, labeling review, and change-control burden.

3. Orally disintegrating tablet

An orally disintegrating tablet, or ODT, is a stronger differentiation strategy than a conventional reformulation. Amitriptyline is bitter, so the excipient system must address taste and not only disintegration time.

A commercially viable ODT platform would typically combine:

• Mannitol or another pleasant-tasting filler
• Crospovidone or croscarmellose sodium
• A compression aid such as microcrystalline cellulose
• A sweetener such as sucralose or acesulfame potassium
• A flavor system
• A taste-masking polymer or coated drug particles
• A low-level lubricant

The central technical risk is the conflict between taste masking and rapid drug release. Polymer coating or ion-exchange resin complexation can reduce bitterness, but excessive coating can delay dissolution and complicate bioequivalence. Amitriptyline’s low dose relative to total tablet mass makes drug-layering or multiparticulate approaches possible.

An ODT would have stronger commercial value for patients with dysphagia, older adults, psychiatric patients, and individuals who have difficulty taking tablets. It would also require a more demanding development program than a conventional tablet.

4. Oral liquid or concentrate

Amitriptyline oral liquid is a meaningful product opportunity because dose titration is common and the marketed tablet strength may not support precise low-dose initiation.

A liquid formulation can use:

• Purified water
• A cosolvent or solubilizer
• A buffer system
• A preservative system
• A sweetener and flavor
• A viscosity modifier
• A taste-masking agent

Amitriptyline hydrochloride is water-soluble enough to support aqueous product development, but the formulation must control pH, precipitation, preservative effectiveness, chemical stability, and palatability. A concentrated product may reduce dose volume but increases the risk of medication errors. A ready-to-use low-concentration liquid has greater patient convenience but higher packaging and shipping costs.

For a US product, a liquid may be pursued through an ANDA if the reference product and regulatory pathway support the required dosage form. A materially different liquid presentation may require a 505(b)(2) application, depending on the reference product, clinical bridging, and FDA determination.[4]

5. Chewable or mini-tablet presentation

A chewable tablet or multiparticulate mini-tablet could support dose titration and pediatric or geriatric administration. Bitter taste remains the principal barrier. The formulation would need robust taste masking, low friability, and dose uniformity at small unit sizes.

This approach could be commercially useful where clinicians require 5 mg, 10 mg, 12.5 mg, or 25 mg increments. The opportunity is stronger when combined with a scored tablet, unit-dose sachet, or calibrated liquid dispenser.

What excipient patents could protect an amitriptyline 25 mg product?

The historical Elavil tablet does not present a meaningful active-ingredient patent estate. Protection for a new amitriptyline product would need to arise from formulation, manufacturing, packaging, or method-of-use claims.

Potential patent categories

Patent category	Potential claim subject	Relative strength
Taste masking	Coated particles, resin complexes, polymer matrices	Moderate if dissolution and sensory data are strong
ODT formulation	Specific excipient ratios, disintegration profile, tablet strength	Moderate; vulnerable to obviousness attacks
Liquid formulation	pH, preservative, cosolvent, concentration, stability	Moderate if technically unexpected
Modified release	Polymer matrix, multiparticulate system, release profile	Stronger if clinically useful and non-obvious
Manufacturing process	Granulation, coating, compression, drying parameters	Moderate but process enforcement is difficult
Packaging	Unit-dose, child-resistant, adherence packaging	Limited unless technically distinctive
Combination product	Amitriptyline with another active or delivery system	Potentially strong but requires clinical and regulatory support

A formulation patent should not rely only on the presence of common excipients. Claims are more defensible when they connect a defined composition to a measurable result, such as a dissolution profile, stability period, reduced bitterness, reduced tablet weight, or controlled plasma exposure.

Method-of-use patents may protect treatment of a defined pain, sleep, migraine, or gastrointestinal population. Their commercial value depends on label language, prescriber behavior, and the ability to enforce the use against generic substitution.

When does Elavil lose exclusivity, and what is the generic entry risk?

Elavil’s original exclusivity expired decades ago. Amitriptyline hydrochloride is an established generic product with no practical US small-molecule exclusivity barrier.

Exclusivity issue	Status
Composition-of-matter patent	Expired
Original brand exclusivity	Expired
Generic availability	Established
Paragraph IV exposure	Relevant only to later patents on a new formulation or use
Biosimilar risk	Not applicable
180-day generic exclusivity	Depends on the specific ANDA and first-filer history
Current market barrier	Manufacturing economics, supply, substitution, and differentiation

A Paragraph IV challenge would matter only if a sponsor obtained a later patent covering an ODT, liquid, modified-release product, taste-masked formulation, or defined method of use. A generic applicant could certify that the patent is invalid, unenforceable, or would not be infringed. The Hatch-Waxman framework can trigger litigation and a 30-month stay in the circumstances specified by statute.[5]

For a conventional 25 mg tablet, the principal competitive threat is not a future generic launch. It is existing generic supply and price compression.

What is the Orange Book status of Elavil 25 mg?

The Orange Book should be reviewed for the current reference-listed-drug designation, therapeutic-equivalence information, discontinued-product status, and any listed patents or exclusivities.[2] Historical Elavil products should not be treated as interchangeable with every current amitriptyline product solely because they contain the same active ingredient.

An ANDA applicant must establish pharmaceutical equivalence and bioequivalence to the applicable reference product. A product with a different dosage form, release profile, concentration, or route may require a different regulatory strategy. FDA’s Inactive Ingredient Database can support excipient selection by identifying prior precedent for route, dosage form, and maximum potency levels.[3]

Which commercial opportunities are strongest for amitriptyline 25 mg?

Opportunity ranking

Product concept	Patient value	Regulatory complexity	Margin potential	Patent potential
Conventional generic tablet	Low	Low	Low	Low
Lactose-free tablet	Moderate	Low	Low to moderate	Low
Scored low-dose tablet	Moderate	Low to moderate	Moderate	Low to moderate
ODT with taste masking	High	Moderate to high	Moderate to high	Moderate
Oral liquid	High	Moderate	Moderate	Moderate
Modified-release capsule or tablet	Moderate to high	High	High	High
Unit-dose adherence package	Moderate	Low to moderate	Moderate	Low
Combination product	Potentially high	High	High	High

The best near-term commercial proposition is a lactose-free, scored immediate-release tablet with multiple strengths and reliable supply. It has manageable development costs and addresses dose titration without requiring a complex clinical program.

The best differentiated proposition is a taste-masked ODT or oral liquid. These products can command higher pricing if they demonstrate meaningful patient-use advantages, but their success depends on palatability, dose accuracy, stability, and prescriber adoption.

A modified-release product has the greatest potential for regulatory and patent differentiation. It also carries the highest development risk because changes in exposure may affect sedation, anticholinergic effects, cardiac safety, and the timing of therapeutic response.

How does amitriptyline compare with competing drugs?

Amitriptyline competes with generic nortriptyline, duloxetine, venlafaxine, gabapentin, pregabalin, trazodone, and low-dose doxepin, depending on the indication. Most competitors are also generic, so formulation convenience and tolerability often matter more than molecule-level exclusivity.

Product	Common formulation advantage	Excipient opportunity
Amitriptyline	Low-dose tablet familiarity	ODT, liquid, titration strengths
Nortriptyline	Capsule and liquid availability in some markets	Palatable liquid and low-dose formats
Duloxetine	Delayed-release capsule	Sprinkle formulation and bead protection
Gabapentin	Capsules, tablets, oral solution	Dose-flexible liquid and unit-dose packaging
Pregabalin	Capsules and oral solution	Pediatric or low-volume liquid
Trazodone	Scored tablets and extended-release products	Better swallowability and dose segmentation
Doxepin	Low-dose and liquid presentations	Sleep-focused dosing formats

Amitriptyline’s disadvantage is its adverse-effect profile, including sedation, anticholinergic effects, orthostatic hypotension, and cardiac toxicity in overdose. An excipient strategy cannot remove these pharmacologic liabilities. It can improve administration, dose titration, and adherence.

What manufacturing and IP barriers affect an amitriptyline formulation?

The active ingredient is not the main manufacturing barrier. The primary barriers are:

1. Taste masking without delayed dissolution.
2. Uniform low-dose distribution in liquids, mini-tablets, and multiparticulates.
3. Stability of preservatives and flavor systems.
4. Control of tablet hardness, friability, and disintegration.
5. Scale-up of granulation or drug-layering processes.
6. Control of excipient variability across suppliers.
7. Packaging that limits moisture, light, and medication errors.
8. Demonstration of bioequivalence for a differentiated dosage form.

For a conventional tablet, process know-how is more valuable than broad composition claims. For an ODT or liquid, the combination of excipient selection, process parameters, sensory testing, and stability data can create a practical barrier even when patent coverage is narrow.

What litigation, settlement, and licensing issues apply?

There is no major active patent-litigation landscape associated with the original Elavil 25 mg tablet comparable to that for recently approved branded drugs. Settlement agreements and Paragraph IV litigation would become relevant only if a new formulation sponsor obtained later-listed patents.

Licensing value could arise from:

• A proprietary taste-masking technology
• A controlled-release platform
• A resin-complexation system
• A pediatric dosing platform
• A specialty packaging or adherence system
• A regional commercial partnership for generic distribution

A licensing deal should allocate ownership of formulation patents, process improvements, regulatory filings, manufacturing know-how, and post-approval changes. For a low-price generic product, royalty economics are likely to favor technologies that support a differentiated dosage form rather than a routine excipient substitution.

What is the revenue exposure and launch outlook?

A conventional amitriptyline 25 mg tablet has limited revenue protection because multiple generic suppliers compete on price. Revenue depends on volume, channel access, supply continuity, and contract pricing.

A differentiated product could improve economics through:

• Higher reimbursement for a new dosage form
• Reduced competition under a 505(b)(2) strategy
• Specialty pharmacy distribution
• Institutional contracts requiring liquid or unit-dose presentations
• Pediatric, geriatric, or dysphagia-focused positioning
• Supply agreements with hospitals and long-term-care providers

The most credible launch scenarios are:

Scenario 1: Low-cost generic tablet

This has the lowest regulatory and manufacturing risk but also the weakest margin and patent position.

Scenario 2: Scored, lactose-free titration product

This offers modest differentiation and can be developed with conventional tableting technology. Its defensibility is limited unless supported by a recognized dosing or packaging advantage.

Scenario 3: Taste-masked ODT

This has stronger patient value and pricing potential. The primary technical and legal assets would be taste-masking performance, dissolution behavior, and formulation claims.

Scenario 4: Oral liquid

This can address dose titration and swallowing difficulty. Commercial success depends on palatability, shelf life, dosing accuracy, and market access.

Key Takeaways

• Elavil 25 mg is an established immediate-release amitriptyline tablet with no meaningful original exclusivity remaining.
• The historical formulation used conventional tablet excipients, including a diluent, starch, lubricant, glidant, and strength-specific colorants.
• A standard generic tablet is commercially accessible but has low margin and weak patent potential.
• The strongest excipient-led opportunities are a lactose-free scored tablet, taste-masked ODT, and stable oral liquid.
• Formulation patents should claim defined compositions linked to measurable performance, not merely common excipient combinations.
• Paragraph IV litigation, settlement agreements, and Orange Book patent strategy become relevant only for later-developed formulations or methods of use.
• Biosimilar risk does not apply because amitriptyline is a synthetic small-molecule drug.
• Manufacturing know-how, palatability, stability, and dose accuracy are more important barriers than the active ingredient.
• A differentiated product should target dysphagia, dose titration, geriatric use, pediatric dosing where clinically appropriate, or institutional supply needs.

FAQs

Can a lactose-free amitriptyline 25 mg tablet be marketed as a generic?

Yes. A manufacturer can develop a lactose-free generic if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and inactive-ingredient acceptability.

Is an amitriptyline 25 mg ODT likely to need new clinical trials?

The requirement depends on the formulation, reference product, route, release characteristics, and regulatory pathway. A bioequivalent immediate-release ODT may avoid large efficacy trials, while a materially different release profile or clinical use may require additional data.

Are excipient changes enough to obtain a new patent?

Usually not. A patent case is stronger when the excipient system produces an unexpected technical result, such as superior taste masking, faster disintegration without delayed dissolution, or improved stability.

Which package is best for an amitriptyline liquid?

A child-resistant, light-protective bottle with a calibrated oral syringe is generally more suitable than a household spoon presentation. Unit-dose packaging may be preferable for institutional or long-term-care use.

Can a new amitriptyline formulation obtain 180-day exclusivity?

180-day generic exclusivity is tied to qualifying first-filer ANDA status and Paragraph IV certifications, not simply to developing a new excipient formulation. A new formulation may instead pursue formulation patents, a 505(b)(2) pathway, or other regulatory protections.

References

1. U.S. Food and Drug Administration. (n.d.). Amitriptyline hydrochloride tablets: Prescribing information and inactive ingredients. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). Guidance for Industry.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).